ASX - Delayed Quote AUD

CardieX Limited (CDX.AX)

0.0590 -0.0040 (-6.35%)
At close: April 26 at 3:59 PM GMT+10
Key Events
Loading Chart for CDX.AX
DELL
  • Previous Close 0.0630
  • Open 0.0630
  • Bid 0.0580 x 281200
  • Ask 0.0580 x 14158300
  • Day's Range 0.0560 - 0.0630
  • 52 Week Range 0.0560 - 0.2997
  • Volume 1,920,153
  • Avg. Volume 351,011
  • Market Cap (intraday) 17.356M
  • Beta (5Y Monthly) 1.52
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date Feb 29, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

CardieX Limited designs, manufactures, and markets medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that measures arterial health by collecting digital vascular biomarkers using novel sensors. The company also provides medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders; and develops and sells medical devices, digital solutions, and wearables for home health, decentralized clinical trials, and remote patient monitoring. It sells its cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company was formerly known as AtCor Medical Holdings Limited and changed its name to CardieX Limited in June 2018. CardieX Limited was founded in 1994 and is based in Sydney, Australia.

cardiex.com

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: CDX.AX

Performance Overview: CDX.AX

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CDX.AX
51.15%
S&P/ASX 200 [XJO]
0.20%

1-Year Return

CDX.AX
82.18%
S&P/ASX 200 [XJO]
3.55%

3-Year Return

CDX.AX
90.30%
S&P/ASX 200 [XJO]
7.53%

5-Year Return

CDX.AX
82.65%
S&P/ASX 200 [XJO]
18.64%

Compare To: CDX.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CDX.AX

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    17.36M

  • Enterprise Value

    16.62M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.70

  • Price/Book (mrq)

    799.39

  • Enterprise Value/Revenue

    1.32

  • Enterprise Value/EBITDA

    -1.95

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -66.44%

  • Return on Assets (ttm)

    -20.08%

  • Return on Equity (ttm)

    -412.13%

  • Revenue (ttm)

    14.16M

  • Net Income Avi to Common (ttm)

    -9.41M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.53M

  • Total Debt/Equity (mrq)

    35,370.68%

  • Levered Free Cash Flow (ttm)

    -481.63k

Company Insights: CDX.AX

People Also Watch